BACKGROUND: Short-term @entity117 therapy can lower the risk for @entity1211 ( @entity1211 ) in high-risk @entity1 , but whether the long-term use of low-dose @entity117 reduces risk in healthy adults is uncertain. OBJECTIVE: To test the efficacy of long-term @entity117 therapy for preventing @entity1211 . DESIGN: Secondary analysis of a 10-year randomized, double-blind, placebo-controlled trial. SETTING: U.S. female health care professionals in the @entity1 's Health Study. @entity1 : 39,876 initially healthy @entity1 age 45 years or older (26,779 gave blood samples that were evaluated for @entity5337 , @entity14553 prothrombin, and @entity9769 @entity9770 polymorphisms). MEASUREMENTS: Documented @entity1211 ( @entity1150 or @entity1151 ) and unprovoked @entity1211 (no recent surgery, @entity130 , or @entity5 diagnosis) were prospectively evaluated, secondary end points. INTERVENTION: @entity117 , 100 mg, or placebo on alternate days. RESULTS: @entity1211 occurred in 482 @entity1 during follow-up, an incidence higher than that of @entity583 and nearly equal to that of @entity64 . The incidence of @entity1211 (per 1000 @entity1 -years) was 1.18 among @entity1 randomly assigned to active @entity117 , compared with 1.25 among @entity1 randomly assigned to placebo (relative hazard, 0.95 [95% CI, 0.79 to 1.13]; rate difference, -0.06 [CI, -0.28 to 0.16]). For unprovoked @entity1211 , the relative hazard was 0.90 (CI, 0.70 to 1.16) and the rate difference was -0.06 (CI, -0.21 to 0.10). Relative hazards associated with @entity117 use in higher-risk subgroups were 0.83 (CI, 0.50 to 1.39) among @entity1 with either @entity5337 or the prothrombin mutation and 1.36 (CI, 0.77 to 2.41) among those with a history of @entity1211 . LIMITATION: @entity1211 was a secondary end point in the @entity1 's Health Study. CONCLUSION: These data suggest that long-term, low-dose @entity117 treatment has little effect on the prevention of @entity1211 in initially healthy @entity1 . ClinicalTrials.gov registration number: NCT00000479.

Effect of low-dose @entity117 on the occurrence of XXXX : a randomized trial.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women', 'person', 'PARTICIPANTS'] @entity5337 :: ('2153', 'Gene') :: ['factor V Leiden'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity9770 :: ('c|SUB|C|677|T', 'DNAMutation') :: ['677C>T'] @entity9769 :: ('4524', 'Gene') :: ['MTHFR'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['Aspirin', 'aspirin'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep venous thrombosis'] @entity14553 :: ('c|SUB|G|20210|A', 'DNAMutation') :: ['G20210A'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['Venous thromboembolism', 'VTE', 'venous thromboembolism'] @entity130 :: ('MESH:D014947', 'Disease') :: ['trauma']
@entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolism']
